AA
SCPH

AlphaCentric Advisors’s scPharmaceuticals SCPH Stock Holding History

AlphaCentric Advisors’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-125,000
Closed -$890K – 279
2023
Q3 		$890K Buy
+125,000
New +$985K 0.5% 70

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

AlphaCentric Advisors's SCPH Position: Q4 2023 in Review

AlphaCentric Advisors sold out of scPharmaceuticals (SCPH) in Q4 2023, closing a stake of 125,000 shares — an estimated $890K sold.

AlphaCentric Advisors first reported a position in SCPH in Q3 2023 and held it in 1 quarter. The position peaked at $890K in Q3 2023. 81 funds tracked by Wall St. Rank hold SCPH as of Q4 2023.

  • AlphaCentric Advisors reported no remaining scPharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • AlphaCentric Advisors sold 125,000 scPharmaceuticals shares in Q4 2023, an estimated $890K.
  • AlphaCentric Advisors first reported a position in scPharmaceuticals in Q3 2023 and held it in 1 quarter.
  • AlphaCentric Advisors's scPharmaceuticals position peaked at $890K in Q3 2023.
  • 81 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2023.

Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.